HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Coordination of care needed to maximize benefit from advances in sickle cell disease
-
- A cancer moonshot: Achieving the unattainable Blase Polite, MD, MPP
- ASH 2015: Several pearls fished from sea of abstracts Harry S. Jacob, MD, DHC
- IP therapy for ovarian cancer: A continued area of debate Martin Gore, PhD, FRCP
- New agents may change standards of care for non-Hodgkin’s lymphoma histologies Jeremy S. Abramson, MD
- OS, surrogate endpoints and the sins of Galileo David J. Stewart, MD, FRCPC
- T-DM1 offers ‘clear’ survival benefit in HER-2–positive metastatic breast cancer Antoinette R. Tan, MD, MHSc, FACP
- Renal Cancer Drugs in the Pipeline
- Preparing for the journey to the moon John Sweetenham, MD, FRCP, FACP
-
- FDA approves Arzerra for extended treatment of CLL
- FDA expands approval of Opdivo plus Yervoy for melanoma
- FDA grants fast track designation to GC4419 for oral mucositis
- FDA grants orphan drug designation to GPX-150 for sarcoma
- FDA grants priority review to Lenvima for advanced renal cell carcinoma
- FDA grants priority review to venetoclax for CLL
- New sclerotic lesions on CT may represent treatment response, not progression of metastatic disease Munir Ghesani, MD, FACNM; Ajit Karakbelkar, MD
- ACP: Risk stratification should guide imaging, testing for suspected PE
-
- Adjuvant GM-CSF, peptide vaccination fail to improve survival for advanced melanoma
- Aromatase inhibitors improve recurrence rates, survival in early breast cancer
- Assisted reproduction feasible for women with breast cancer history
- Biden to lead effort to expedite cancer research, find a cure
- Black women face worse endometrial cancer outcomes regardless of tumor type
- Cabozantinib superior to everolimus in advanced kidney cancer
- Cetuximab may benefit select patients with NSCLC
- Changing 25-hydroxyvitamin D3 levels may predict poorer melanoma survival
-
- Contralateral prophylactic mastectomy incidence increases among men with breast cancer
- ETV6 variations may predict predisposition to childhood ALL
- False-positive mammograms may cause long-term psychosocial effects
- Forced expiratory volume in 1 second predicts sickle cell anemia death
- High-dose dexamethasone confers favorable outcomes in adult primary ITP
- Histologic regression may predict SLNB benefit in melanoma
- IGHV mutation without 11q, 17p deletions defines very low-risk CLL subgroup
- Incidence of high-grade cervical lesions has declined due to screening, vaccination
-
- Interferon alpha confers hematological, molecular benefits in essential thrombocytopenia
- Intestinal obstruction a long-term risk for survivors of childhood cancer
- Iron dextran carries greatest anaphylaxis risk of marketed IV iron products
- Left atrium volume predicts mortality among patients with PE
- Lung cancer screening does not increase unnecessary surgeries
- Management of localized prostate cancer has improved in community-based practices
- Metformin combination slightly lowers breast cancer risk among women with diabetes
- Novel assay shows promise in evaluating bleeding risk with new oral anticoagulants
-
- Oral contraceptives may improve OS in patients with epithelial ovarian cancer
- PD-L1 expression predicts survival in DLBCL
- Persistent HPV16 DNA in oral rinses predicts oropharyngeal cancer recurrence
- Preoperative PET/CT staging yields high false-positive rate in node-positive melanoma
- RAD51 mutations may increase risk for epithelial ovarian cancer
- Sirolimus shows promise for pediatric ALPS
- Social, economic factors contribute to OS outcomes among younger patients with AML
- Stress and cancer: Mindfulness is pivotal component to improve outcomes
-
- Surrogate endpoints may not predict OS in oncology clinical trials
- Switch from LMWH to dabigatran prevents VTE after orthopedic surgery
- Thyroid cancer diagnosis, treatment linked to decreased quality of life
- Treatment cessation noninferior to radiation for PET-negative Hodgkin's lymphoma
- Vemurafenib effective in relapsed, refractory hairy cell leukemia
- Breast cancer surgeon joins Henry Ford Health System
- Aflac Cancer and Blood Disorders Center names director
- American Cancer Society presents Medal of Honor to four individuals, one foundation
-
- Gynecologic surgeon joins Meridian Health
- Informatics director assumes expanded role
- Medical oncologist, researcher joins City of Hope
- Memorial Sloan Kettering Cancer Center announces appointments
- NCCN awards grants for study of enzalutamide, volasertib
- UTHealth physician joins NCI board
- CarPac pre-op chemoradiation benefits patients with resectable esophageal cancer
- Daratumumab combination confers durable responses in relapsed, refractory multiple myeloma
-
- Everolimus delays progression of neuroendocrine tumors
- Ibrutinib combination confers significant benefit in relapsed CLL
- Lutathera improves outcomes in metastatic midgut neuroendocrine tumors
- Nivolumab monotherapy shows promise in treating gastric, GE junction cancers
- Oncologists, PCPs disagree on who should provide cancer survivorship care
- Persistent CIPN causes impaired physical functioning, falls in women cancer survivors
- Personalized survivorship plans improve outcomes among low-income breast cancer survivors
- Short-course chemoradiation regimen effective, less toxic for advanced rectal cancer
-
- Vistogard effectively treats 5-FU chemotherapy toxicity